Ozempic & Semaglutide: Transforming Metabolic Treatment Kumar Jeetendra | March 30, 2026 For a number of years now, healthcare systems globally have centered their attention on improving metabolic health. The sharp rise of obesity and type 2 diabetes has highlighted the urgent require for treatments that are not only efficient but also sustainable. One of the most pioneering treatments has been Semaglutide or Ozempic. It has been …
Alembic Pharma Secures USFDA Tentative Approval for Bosutinib Kumar Jeetendra | February 9, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Bosutinib Tablets, 400 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Bosulif Tablets, 400 mg, of PF Prism C.V. (PF Prism …
2025 in Review: A Defining Year for Pharma, Laboratory & Analytical Industry Kumar Jeetendra | January 6, 2026 By the end of 2025, the pharma, laboratory, and analytical sectors will have undergone an unprecedented overhaul. These industries overcame the pandemic bounce-back and are now completely transformed. Digital tools, regulatory oversight, analytical efficiency, and manufacturing breakthroughs have all advanced these markets.For scientists, manufacturers, solution providers, and leaders in these sectors, 2025 was about operational …
Alembic Pharma Gets USFDA Nod for Diltiazem HCl Tablets Kumar Jeetendra | November 17, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 …
Alembic Gets USFDA Nod for Sumatriptan Injection Autoinjector Kumar Jeetendra | November 10, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Imitrex STATdose System, …
Common mistakes in pharma equipment disinfection and how to avoid them Kumar Jeetendra | November 9, 2025 A few months back, a leading Indian pharmaceutical company lost an entire production batch, bearing almost a ₹20 crore loss. The culprit was a tiny trace of residue on a mixing blade. No formulation error. No equipment failure. Just inadequate disinfection. These stories don’t make headlines, but they’re far more common than the industry likes …
Alembic Pharma Gets USFDA Nod for Ticagrelor 60 mg Tablets Kumar Jeetendra | November 1, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 60 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Brilinta Tablets, 60 mg, of AstraZeneca Pharmaceuticals LP (AstraZeneca). Ticagrelor tablets are …
Alembic & Amlan Launch MinerTox-Z and MinerTox-A Kumar Jeetendra | October 9, 2025 Alembic Pharmaceuticals Ltd., through a strategic agreement with Amlan International, today announced the India launch of MinerTox-Z and MinerTox-A, feed additive solutions developed to protect poultry against toxins and enhance farm productivity. The introduction of these products represents an important step in addressing one of the poultry industry’s most pressing challenges—losses caused by toxins. By …
Pharma 2030: AI, Automation & The Next Era of Drug Development Kumar Jeetendra | October 6, 2025 For the first time in its chronicle, the pharmaceutical industry is on the verge of crossing a transformative threshold. The next decade and a half will not focus on the completion of incremental improvements but on the determining of a new paradigm in the intricate relationship of science and technology. The paradigm will focus on …
Alembic Pharma Gets EIR for API-I & II Facility at Panelav Kumar Jeetendra | September 15, 2025 Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) for the inspection conducted by the US Food and Drug Administration (USFDA) at its API-I and API-II facilities in Panelav. The inspection was carried out between May 26, 2025 and May 31, 2025. About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and …
Cipla Launches HUENA®, India’s First Non-Antibiotic UTI Drug Kumar Jeetendra | September 8, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for Cipla in the fight against Anti-Microbial Resistance (AMR) and reinforces its commitment …
Enteromix: Russia’s mRNA Vaccine for Colon Cancer Kumar Jeetendra | September 7, 2025 The Eastern Economic Forum, which took place from September 3 to September 6, 2025, in Vladivostok and is known for its landmark announcements, heard for the first time about Russia’s mRNA-based cancer vaccine, Enteromix, from the Federal Medical and Biological Agency (FMBA) of Russia. As per the available information, the vaccine has passed the preclinical …
